Celldx™
Unlocking Genetic Insights for Targeted Cancer Therapy
Unlocking Genetic Insights for Targeted Cancer Therapy
Celldx™ is a comprehensive genomic test to identify actionable therapy options based on guideline-recommended genes for tumours that occur in solid organ systems of the body.
Celldx™ is a next-generation sequencing-based in vitro diagnostic test that simultaneously detects various cancer relevant and clinically actionable genomic alterations such as Single Nucleotide Variants (SNVs), short Insertions and Deletions (InDels), Copy Number Alterations (CNAs), fusions/rearrangements, Tumour Mutational Burden (TMB), Microsatellite Instability (MSI), and PD-L1 status.
Celldx™ is ideal if you are diagnosed with cancer that requires molecular profiling to explore personalized therapies designed to 'target' cancer cells in your body without affecting the normal cells or to stimulate or suppress your 'immune system' to help the body fight cancer.